Multiple sclerosis (MS) and neuromyelitis optica (NMO) are inflammatory demyelinating disorders of the central nervous system with evidence of antibody-mediated pathology.
Immunoglobulin G (IgG) deposition is a seminal feature of active MS and NMO lesions (Breij et al., 2008; Lucchinetti et al., 2000; Lucchinetti, Bruck, & Lassmann, 2004) . Clinical and experimental data have demonstrated that AQP4-IgG is specific (range 96-99%) for NMO and capable of reproducing diseasespecific pathology ex vivo and in vivo. In contrast, the targets of the intrathecal humoral response in MS and their relationship to disease pathogenesis are poorly understood. In surveys of biopsy-and autopsy-derived MS tissues (Breij et al., 2008; Lucchinetti et al., 2000) , the most prevalent active lesion subtype (type II) was defined by deposition of Ig and terminal complement at the lesion edge and within macrophages indicating that antibody-and complementmediated myelin phagocytosis likely play a central role in demyelination in MS patients. A robust and sustained humoral response within the CNS of MS patients is a biochemical hallmark of disease as evidenced by persistent CSF IgG oligoclonal bands and B cell clonal expansion (Hemmer, Cepok, Zhou, & Sommer, 2004; Ritchie et al., 2004) .
We have produced IgG1 monoclonal recombinant antibodies (rAbs) from clonally expanded plasmablasts recovered from NMO ) and MS (Blauth et al., 2015; Owens et al., 2009 ) patient CSF. Patient-derived AQP4-specific monoclonal rAbs have been used to direct targeted destruction of primary murine astrocytes and mixed glial cultures in vitro (Liu et al., 2016; Tradtrantip et al., 2012) , cerebrum and spinal cord demyelination ex vivo (Liu et al., 2017; Liu et al., 2016; Tradtrantip et al., 2012; Yao et al., 2016; Yao & Verkman, 2017; Zhang, Bennett, & Verkman, 2011) , and NMO disease-specific histopathology in vivo Bradl et al., 2009; Ratelade & Verkman, 2014; Saadoun et al., 2010; Tradtrantip et al., 2012) . NMO lesions in model systems are dependent on both the AQP4-specificity and effector function of the administered IgG, consistently demonstrating that AQP-IgG is necessary and sufficient for NMO lesion formation. By contrast, CSF-derived rAbs from early active MS patients (Blauth et al., 2015; Liu et al., 2017) have demonstrated 2 patterns of CNS immunoreactivity.
Pattern 1 rAbs bind to neurons, neuropil and astrocytes in CNS tissues, while Pattern 2 bind to the surface of oligodendrocyte processes and myelinating axons. When applied to organotypic cerebellar slice cultures ex vivo, myelin-specific MS rAbs cause robust oligodendrocyte loss, demyelination, and microglia activation; however, astrocytes, OPCs and neurons remain unaffected [Liu et al., 2017] . The injury is distinct from that induced by AQP4-specific NMO rAb which results in astrocyte destruction, oligodendrocyte loss, demyelination, microglia activation, and neuronal death (Liu et al., 2017) .
In this study, we evaluated the recovery of cerebellar explants following MS and NMO rAb-mediated injury and observed distinct patterns of glial responses that were coupled with disparate capacities for remyelination. Our results highlight key differences in MS and NMO lesion repair and establish a novel model system for evaluating mechanisms and therapies that may impact recovery in two major human inflammatory demyelinating disorders.
| MATERIALS AND METHODS

| Animals
The care and euthanasia of animals are in accordance with University of Colorado IACUC policy for animal use, which is in agreement with the NIH Guide for the Care and Use of Laboratory Animals.
| Recombinant antibodies
Disease-specific and isotype control monoclonal recombinant antibodies (rAbs) MS#30, NMO#53, and ISO were derived from expanded CSF plasma blast clones recovered from patients with relapsingprogressive MS (Owens et al., 2009 ), AQP4-seropositive NMO , and idiopathic chronic meningitis (Blauth et al., 2015) , respectively. All rAbs were expressed as full-length bivalent human IgG1 antibodies using a dual vector transient transfection system and purified with protein A-sepharose (Sigma-Aldrich, St. Louis, MO) as previously described Owens et al., 2009 ). All rAbs were used at 20 μg/mL in the slice cultures.
| Cerebellar slice culture
Sagittal cerebellar slices (300 μm) were prepared from PLP-eGFP mice (Mallon, Shick, Kidd, & Macklin, 2002) at P10 and cultured on MilliCell 0.4 μm membrane inserts (Millipore, Billerica, MA) in slice media (25% Hank's balanced salt solution (HBSS), 25% heat-inactivated horse serum, 50% minimum essential media (MEM), 125 mM HEPES, 28 mM D-Glucose, 2 mM L-Glutamine, 10 U/mL penicillin/streptomycin, all from Life Technologies, Carlsbad, CA) at 37 C (Sheridan & Dev, 2012) . Slices were cultured for 7-10 days prior to treatment.
| Treatment of cerebellar slices
rAbs were applied at 20 μg/mL with 10% (vol/vol) normal human serum (Complement Technology, Tyler, TX) as a source of complement. Cerebellar slices were exposed to media containing treatment reagents both on top (50 μL) and below (240 μL) the membrane inserts for 24 or 48 hr, and then were washed and cultured for additional 7-14 days.
| Immunostaining
After treatment, cerebellar slices were rinsed twice with PBS and fixed in 4% paraformaldehyde in PBS for 20 min at room temperature. For immunohistochemistry, slices were rinsed in PBS and permeabilized in 1.5% or 10% (myelin proteins) Triton X-100 in PBS for 20 min. Slices were rinsed, blocked with 5% normal donkey serum (NDS) in PBS with 0.3% Triton X-100 for 1 hr, and incubated with primary antibodies over- 
| RESULTS
We have previously demonstrated that patient-derived MS myelinspecific and NMO AQP-specific rAbs bind to the surface of oligodendrocyte processes and astrocytes, respectively (Supporting Information Figure S1 ; [Liu et al., 2017; Liu et al., 2016] ). Due to their distinct glial cell targets, patient-derived MS and NMO rAbs cause distinct patterns of glial and neuronal injury in ex vivo organotypic cerebellar slice cultures (Liu et al., 2017) . In this study, we examined the recovery of explanted cerebellar tissue following MS and NMO rAb-mediated damage.
3.1 | Mature oligodendrocytes repopulate following treatment with MS rAb and human complement Cerebellar slice cultures prepared from PLP (proteolipid protein)-eGFP mice (Mallon et al., 2002) were treated with myelin-specific MS rAb, MS04-2 #30 (MS#30) or isotype control rAb (ISO) (Blauth et al., 2015) plus 10% human complement (HC) for 24 hr. Following treatment, rAb and HC were removed by media exchange, and slices were allowed to recover in culture media (in the absence of rAb+HC) for an additional 14 days ( Figure 1a ). In agreement with our prior published results (Liu et al., 2017) , following 24 hr of treatment (T0) with MS#30+HC, eGFP+ oligodendrocyte cell bodies were reduced to 52.8 AE5.4% of control slices treated with ISO+HC, and oligodendrocyte processes were fragmented and disrupted. After 3 days of recovery (T3), eGFP+ oligodendrocyte cell bodies and processes began to repopulate the folia. At T7, oligodendrocyte cell bodies had recovered to 99.4 AE5.1% of control levels (ISO + HC at T0) and oligodendrocyte processes were extensive and well-organized (Figure 1b (Emery et al., 2009; Liu et al., 2016) . Similarly, after recovery from treatment with MS#30+HC, most PLP-eGFP+ oligodendrocytes were CC1+, indicating that regenerated oligodendrocyte cells were well-differentiated (Supporting Information Figure S2 ). The number of mature myelinating oligodendrocytes was assessed by GST-pi+ (pi form of glutathione-S-transferase) immunostaining (Tamura et al., 2007) (Figure 2a ). After exposure to MS#30+HC, the number of GST-pi+ oligodendrocytes was significantly reduced at T0
(57.4 AE4.8%); however, by T7 the number had recovered to 102.3 AE8.1% of untreated control slices. At T7, approximately 75% of PLP-eGFP+ cells were GST-pi+, similar to that observed in untreated slices ( Figure 2b ). Together, these results demonstrate that the rapid loss of oligodendrocyte cells induced by treatment with MS rAb plus complement is followed by robust regeneration, differentiation, and maturation into myelinating cells.
| Efficient remyelination after MS#30+HC-mediated demyelination
We next investigated whether the regenerated myelinating oligoden- and demyelination (91.0 AE8.6%) (Liu et al., 2017) .
| Remyelination following MS rAb-induced injury is associated with microglia but not astrocyte activation
Astrocyte morphology and number were evaluated following treatment with MS#30+HC using GFAP (glial fibrillary acidic protein), AQP4, and S100b (S100 calcium-binding protein B) immunostaining.
Consistent with our previous report (Liu et al., 2017) , demyelination with MS rAb had no immediate effect on astrocyte morphology or network structure, and there were no additional changes during the 7 days of remyelination ( Figure 4a ). Astrocyte cell number also remained unchanged following injury and during oligodendrocyte recovery (Figure 4b,c) .
Microglia cell number and activation was assayed by Iba1 (ionized calcium binding adaptor molecule 1) immunostaining ( Figure 5 ).
Increased numbers of Iba1+ microglia were observed in MS#30+HC-treated slices relative to ISO+HC sections at T0 (56.5 AE8.3%). As recovery ensued, the number of microglia peaked at T3 (39.5 AE8.1%
increase from T0, more than double the number of microglia compared to ISO+HC) followed by a decline to IC+HC levels by T7 (Figure 5a,b) . Microglia in MS#30+HC sections altered their appearance from a ramified morphology to an ameoboid-like shape consistent with activation (Salter & Stevens, 2017) . From T0 to T3, microglia (Supporting Information Figure S4c ).
3.4 | Oligodendrocytes repopulate but fail to remyelinate following NMO rAb-induced damage AQP4-specific NMO rAb treatment initiates complementdependent astrocyte destruction followed by loss of oligodendrocytes and demyelination (Liu et al., 2017) . Cerebellar slice cultures were treated with NMO rAb#53 (NMO#53)+HC for 24 hr, washed, and then recovered in culture media for 7 days (Figure 6a ). 49.9 AE8.6% of control at T0, to 73.9 AE3.5% at T3, and 95.2 AE8.3%
at T7 (Figure 6b ,c; S100b panels).
We next examined whether astrocyte repair coincided with oligodendrocyte repopulation and myelin regeneration. The number of PLPeGFP+ oligodendrocytes and Sox10+ oligodendrocyte lineage cells was significantly greater in the slices at T7 than T0 (Figure 7a ). At T7, the numbers of PLP-eGFP+ and Sox10+ cells were restored to 100.1 AE7.5%
and 93.8 AE9.6% of ISO+HC control slices, respectively (Figure 7c ). All the PLP-eGFP+ oligodendrocyte cells recovering from NMO#53+HC treatment were CC1+, indicating that regenerated oligodendrocyte cells had differentiated to the early myelinating stage (Supporting Information Figure S2 ). Despite restoration of oligodendrocyte numbers, the extension of eGFP+ processes from oligodendrocyte cell bodies was limited and fragmented in appearance (Figure 7a , high magnification PLP-eGFP panels). In contrast, oligodendrocyte processes were extensive and wellorganized at T7 in slices recovering from treatment with MS#30+HC
( Figure 1b , high magnification PLP-eGFP panels). Moreover, the number of GST-pi+ oligodendrocytes remained significantly reduced (48.7 AE3.4% to untreated controls) when compared to MS#30+HC slices at T7 (Figure 7b,c) . Hence, in NMO rAb+HC treated slices, differentiated early myelinating oligodendrocytes (CC1+) repopulate but do not mature fully (GST-pi+).
Consistent with the lack of oligodendrocyte maturation, slices treated with NMO#53+HC showed no restoration of axonal ensheathment or paranode immunostaining at T7 (Figure 7d and data 
| Reduced microglia activation following NMO#53+HC-induced injury
Similar to that observed after treatment with MS#30+HC, Iba1+ microglia were significantly increased at T0 following exposure to NMO#53+HC (Figure 8a ). However, in contrast to MS rAb-treated slices, both total Iba1+ cell number and the reactive-shaped Iba1+ cells gradually reduced during recovery from NMO rAb-induced 
| DISCUSSION
We have previously demonstrated that patient-derived MS and NMO rAbs target disease-specific epitopes resulting in distinct patterns of glial and neuronal injury (Liu et al., 2017 ). In the current study, we demonstrate that these disease-specific injuries establish distinct environments that alter glial cell responses and remyelination ( Remyelination has been studied in ex vivo and in vivo animal models and shown to be quite robust (Verden & Macklin, 2016) . In remyelination from lysolecithin-induced demyelination occurs 7-14 days after treatment removal (Birgbauer, Rao, & Webb, 2004; Miron et al., 2010; Zhang, Jarjour, Boyd, & Williams, 2011) . We observed a similar time frame for remyelination of cerebellar slices after inflammatory demyelination induced by MS rAb and complement. Remyelination is often inefficient and limited in MS patients, leading to permanent deficits and dysfunction (Louapre et al., 2015; Lucchinetti et al., 2000) , and there are no therapies proven to repair myelin damage in MS (Harlow, Honce, & Miravalle, 2015) . Under- There is limited histopathologic description of remyelination in human NMO lesions (Ikota, Iwasaki, Kawarai, & Nakazato, 2010) . This is due in part to our limited understanding of the dynamics of NMO lesion formation and repair in vivo. NMO lesions demonstrate combined astrocyte, oligodendroglial, and neuronal pathology that likely limit remyelination through diverse mechanisms: (a) inhibition of oligodendroglial differentiation; (b) inhibition of OPC migration through blood-brain barrier injury; and (c) impaired myelin wrapping secondary to irreversible axonal destruction (reviewed in (Weber, Derfuss, Metz, & Bruck, 2018; Yao et al., 2016) . It is unclear how primary astrocyte destruction results in downstream oligodendrocyte loss, myelin destruction, and neuronal injury in NMO lesions. Potential pathogenic mechanisms include excitotoxicity, altered ion homeostasis, increased In our ex vivo cerebellar model, CC1+ differentiated oligodendrocytes were regenerated but failed to mature to the myelinating stage despite the restoration of astrocyte cell numbers and morphology. Yao et al. (2016) reported a similar lack of remyelination in cerebellar slices treated with AQP4-specific antibody and human complement.
Using low concentrations of AQP4 rAb and human complement, they observed reduced CC1+ oligodendrocyte differentiation. The difference in oligodendrocyte differentiation observed herein may be due to different genetic backgrounds (CD1 vs C57) and/or sources of human complement. Differential OPC damage might also account for the reduced oligodendrocyte differentiation into CC1+ cells in that study (Yao et al., 2016) . In this study, recovery of slices from 24 hr treatment of NMO#53+HC myelin involved increased deterioration and fragmentation of axons at T7 and T14 (Figure 7 ). It is possible that lack of remyelination leads to neuronal injury as indicated by fragmented axons. Alternatively, injured neurons and reduced neuronal activity (Liu et al., 2017) may have reduced signals that enhance oligodendrocyte ensheathment or produced inhibitory signals that block oligodendrocyte maturation and myelination (Mount & Monje, 2017 ).
Although we and others have observed a rapid repopulation of astrocytes in cerebellar slices recovering from NMO rAb-mediated damage, the regenerated cells may not function equivalently to nascent astrocytes during recovery (Figure 7 ). There is abundant and growing evidence for astrocytes to actively participate in both MS lesion development and repair (Brosnan & Raine, 2013) . It has been
shown that reactive astrocytes are key players in driving CNS inflammation and are directly implicated in suppressing remyelination in an EAE model (Brambilla et al., 2014) . Further characterization of the sub-type and function of repaired astrocytes in lesions may reveal the role of astrocyte in remyelination suppression.
We previously reported that approximately 50% of OPCs are lost in slices treated with rAb NMO#53+HC, whereas slices treated with MS#30+HC show no reduction in OPCs (Liu et al., 2017; Liu et al., 2016) . The equivalent repopulation of oligodendrocytes after both MS-and NMO-mediated injury in the current study demonstrates that initial OPC differentiation was not impaired by NMO rAb-mediated injury despite a lower number of surviving cells. However, the failure of oligodendrocytes to reach a functional myelinating stage following NMO#53-mediated injury indicates that the milieu produced by NMO-specific rAbs is not conducive to full recovery, while that produced by myelin-specific MS rAbs is distinctly conducive to complete remyelination.
We observed a significant difference in microglia activation following MS and NMO rAb-mediated injury (Table 1) . Microglial numbers and reactivity increased in slices recovering from MS rAb +HC-induced damage ( Figure 5 ), whereas microglial activation continually declined during recovery from NMO rAb demyelination (Figure 8 ). Microglia are the principal resident immune cells in the CNS and play an essential and versatile role in CNS development, maintenance, repair (Sierra et al., 2016) and in pathological context (Salter & Stevens, 2017; Wieghofer, Knobeloch, & Prinz, 2015) . Microglia function in remyelination likely involves phagocytosis of myelin debris and the secretion of factors to recruit OPCs and promote oligodendrocyte regeneration (Lloyd & Miron, 2016; McMurran, Jones, Fitzgerald, & Franklin, 2016; Olah et al., 2012 (Ramanathan, Dale, & Brilot, 2016) .
MOG-IgG, however, is rarely identified in MS patients (Peschl, Schanda, et al., 2017) . The MS patient-derived, myelin-specific rAbs used in this study (MS#30 and MS#49) are not directed against MOG (Blauth et al., 2015; Owens et al., 2009) (Peschl, Bradl, Hoftberger, Berger, & Reindl, 2017 ). Additionally, when tested alongside anti-AQP4 NMO rAb, intracerebral micro-injection of MOG-positive serum IgG failed to induce CNS demyelination (Saadoun et al., 2014) . Therefore, the complement-mediated effects of MS patient-derived myelin-specific rAbs on organotypic cerebellar slices are not merely representative of any myelin-specific autoantibody but reflect MS-specific injury.
In summary, identifying distinct glia responses and effects on myelin repair in MS and NMO will lead to a better understanding of the mechanisms governing remyelination in these distinct disorders.
This information will be crucial for the successful development of distinct therapeutic strategies to facilitate recovery in affected patients.
Our results suggest that microglia activation may play a crucial role in promoting oligodendrocyte maturation and effective remyelination.
Importantly, astrocyte recovery is insufficient to drive oligodendrocyte maturation in NMO lesions. Our novel ex vivo models of rAbmediated demyelination/remyelination will serve as new experimental models to identity potential therapies that promote effective remyelination in MS or NMO. We are indebted to Adeline Matschulat, Kimberley ClawsonStone and Hannah Schumann for the preparation of recombinant antibodies. We thank Kristin Schaller for assistance with mouse breeding.
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